GNS – DirectorsTalk Interviews https://www.directorstalkinterviews.com LSE London Stock Exchange PLC Company Interviews Thu, 22 Aug 2019 06:35:25 +0000 en-GB hourly 1 https://wordpress.org/?v=5.2.3 Genus plc appoints Stephen Wilson as CEO from 13 September 2019 https://www.directorstalkinterviews.com/genus-plc-appoints-stephen-wilson-as-ceo-from-13-september-2019/412791010 Thu, 22 Aug 2019 06:35:24 +0000 https://www.directorstalkinterviews.com/?p=791010 Genus plc (LON:GNS), a leading global animal genetics company, today announced that Stephen Wilson, currently Group Finance Director, has been appointed by the Board as Chief Executive with effect from the close of business on 13 September 2019. This follows the announcement of 25 March 2019 that Karim Bitar will be stepping down from the Board ...

This article Genus plc appoints Stephen Wilson as CEO from 13 September 2019 was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc (LON:GNS), a leading global animal genetics company, today announced that Stephen Wilson, currently Group Finance Director, has been appointed by the Board as Chief Executive with effect from the close of business on 13 September 2019. This follows the announcement of 25 March 2019 that Karim Bitar will be stepping down from the Board and taking up the position of Chief Executive of another company.

Stephen has been with Genus since January 2013 and already has a very strong and deep understanding of Genus and has been an integral part of the team in the successful strategic and operational development of the Group in recent years, as it has continued to grow and strengthen its position as a world leader in animal genetics. Stephen was by far the strongest candidate for the role following a review of both external and internal candidates managed by an external search agency.

Stephen’s current finance responsibilities will be undertaken by Janet Duane, currently Group Financial Controller on an interim basis. A search for a permanent replacement Group Finance Director has already been initiated by an external agency.

Bob Lawson, Chairman of Genus, commented on Stephen’s appointment;

“Genus is extremely fortunate to have such a strong individual in Stephen Wilson to fill the role of Chief Executive. Stephen has already had  significant strategic and operational input in the development of Genus and no one knows the business better than him.

“We are delighted that Stephen will drive Genus through the next stage of our continued growth, and it is clear that Genus is, and will continue to be, in strong hands.”

This article Genus plc appoints Stephen Wilson as CEO from 13 September 2019 was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc Strategic porcine collaboration in China https://www.directorstalkinterviews.com/genus-plc-strategic-porcine-collaboration-in-china/412782629 Thu, 16 May 2019 11:18:53 +0000 https://www.directorstalkinterviews.com/?p=782629 Genus plc (LON: GNS), a leading global animal genetics company, today announced that it has entered into a strategic porcine collaboration in China, the world’s largest pork market. The collaboration, which is with Beijing Capital Agribusiness Co. Ltd (“BCA”), is to research, develop, register and market in China elite PIC pigs that are resistant to ...

This article Genus plc Strategic porcine collaboration in China was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc (LON: GNS), a leading global animal genetics company, today announced that it has entered into a strategic porcine collaboration in China, the world’s largest pork market. The collaboration, which is with Beijing Capital Agribusiness Co. Ltd (“BCA”), is to research, develop, register and market in China elite PIC pigs that are resistant to Porcine Reproductive and Respiratory Syndrome virus (“PRRSv”). BCA has a leading Chinese animal protein genetics business and is owned by the Beijing Capital Agribusiness and Food Group (part of the Beijing Municipality), GLP-Youshan Fund and CITIC Agriculture (“CITIC”), a division of one of the largest state-owned conglomerates in China.

Under the terms of the strategic collaboration, Genus will receive:

· upfront and milestone cash payments totalling US$20m subject to certain conditions being fulfilled;

· between US$120m-$160m for the creation with BCA of a joint venture, including Genus’s existing PIC operations in China, in several years’ time after the required regulatory approval of PRRSv resistant pigs has been obtained in China; and

· intellectual property royalties from the joint venture on sales in China of PRRSv resistant pigs.

The Collaboration

The initial phase of the collaboration, which is expected to take several years, focuses on the research, development and regulatory approval in China of PRRSv resistant pigs. BCA will establish and fund a specific, wholly owned corporate entity for the purposes of the collaboration which will be called Beijing Shou Nong Future Bio-Tech Co., Ltd. (“BCA Future Bio-Tech”). BCA Future Bio-Tech and Genus also intend to cooperate to research and develop solutions to other major challenges facing the Chinese pork industry including African Swine Fever. At the same time the parties will explore ways to accelerate the use of PIC genetics in China through the phased integration of PIC genetics into BCA’s current 6,000 sow capacity breeding facilities and their planned major expansion in response to the shortage of quality breeding stock in China caused by African Swine Fever.

Genus will grant a technology licence to BCA Future Bio-Tech for intellectual property rights and transfer know-how to enable BCA Future Bio-Tech to undertake the PRRSv resistance development and regulatory work in China. This will be funded exclusively by BCA and is expected to cost several tens of millions of US dollars and take several years. BCA Future Bio-Tech plans to work collaboratively with Chinese regulatory authorities to seek approval of the gene edited pigs, while focussing on animal well-being and bio-security practices.

Following Chinese regulatory approval and the launch of PRRSv resistant pigs in China, Genus and BCA have agreed that they will work together in a joint venture which will include Genus’s existing PIC operations in China (“PIC China”). A framework agreement has been entered into governing the transaction and the proposed joint venture between Genus and BCA.

Background to the Collaboration

As China seeks to modernise its pork production, these efforts are significantly hindered by disease outbreaks. PRRSv is one of the most harmful pig diseases in China, together with African Swine Fever and Foot and Mouth Disease. PRRSv affects the majority of pigs in China and causes animal suffering, reproductive failure, increased mortality and reduced growth. There is currently no cure for PRRSv.

Genus has been able to breed pigs that demonstrate resistance to PRRSv. This breakthrough has been confirmed by several independent studies. Genus has the exclusive global rights to this technology and is working constructively with the US Food and Drug Administration to obtain regulatory approval in the US to commercialise PRRSv resistant pigs in a responsible way. PRRSv resistant pigs have great potential to improve animal well-being, the environmental sustainability of pig production, farm productivity and benefit consumers by significantly reducing the use of antibiotics.

The potential to reduce PRRSv will bring significant benefits to China, improving the reliability of the pork supply chain and helping to provide safe and high-quality pork to Chinese consumers, while benefiting pig farmers who will see a reduction in disease outbreaks. By minimising the prevalence of PRRSv, BCA Future Bio-Tech could help accelerate the development of a sustainable Chinese pork industry and reduce government spending on disease control.

The Transaction

Under the terms of the transaction, Genus will receive cash consideration under the development and technology licence agreement of US$20m, in aggregate, upon the satisfaction of certain commercial and regulatory milestones relating to the development programme. US$13m of the commercial and regulatory milestone payments will be creditable against future intellectual property royalty payments to Genus.

Following receipt of regulatory approval in China for PRRSv resistant pigs in several years’ time, the PIC China business will be combined with BCA Future Bio-Tech to form a joint venture which will be 51% owned by BCA and 49% owned by Genus. Under the terms of the combination, Genus will receive a further cash payment based on the performance of PIC China in the three years prior to the combination, with a floor of US$120m and cap of US$160m. This payment will be further adjusted to reflect any difference between the cash or net debt balance of BCA Future Bio-Tech and PIC China. The PIC China – BCA Future Bio-Tech joint venture will pay intellectual property royalties to Genus on the sales of PRRSv resistant pigs in China.

The Genus board will consider the appropriate use of the US$ cash proceeds derived from the formation of the joint venture at the time based on Genus’s financial position and prospects.

The transaction constitutes a Class 2 transaction for the purposes of the UK Listing Rules. For the purposes of Listing Rule LR 10.4.1 R, as at 30 June 2018, the total book value of gross assets attributable to PIC China were approximately £31m.(1) In the year to 30 June 2018, the pre-tax profits attributable to PIC China were approximately £6m.(2) Completion of the transaction is subject to customary Chinese regulatory approvals.

Comments on the Collaboration

Karim Bitar, CEO of Genus, said: “Today’s announcement represents a very important step in our PRRSv resistance program. The collaboration with BCA with full support from its shareholders in the food and agriculture space, Beijing Capital Agribusiness & Food Group and CITIC Agriculture, can accelerate the availability of PRRSv resistant pigs as well as PIC’s leading porcine genetics in China and validates our ongoing investment in this initiative. BCA is a strong long-term partner to co-develop and co-market this technology in China, the largest pork market in the world. BCA brings a unique market place understanding of the Chinese pork industry and customer landscape, as well as robust regulatory capabilities, and understand the importance of developing this technology collaboratively and responsibly.”

Bill Christianson, COO of Genus PIC said “The combination of PIC’s PRRSv resistant genetics and related breeding knowhow along with BCA’s deep understanding of the porcine sector in China and its distribution channels plays to the strengths of each party. We are looking forward to rapidly progressing the PRRSv resistance program in collaboration with BCA and launching this important new product in China with our partners.”

Liu Jiantong, General Manager and Vice Chairman of Beijing Capital Agribusiness Co., Ltd., said: “We are excited to collaborate with Genus PIC, the world’s leading porcine genetics company, for the registration and launch of PRRSv resistant pigs in China as an important step of a broader partnership. BCA is a leading agricultural company that focuses on providing high quality and modern technology to Chinese animal protein producers. Our exclusive collaboration with Genus PIC in China on this cutting-edge technology and other future ventures further expands BCA’s presence in the animal protein genetics sector and is consistent with BCA’s long-term strategy.”

Mao Changqing, CEO of CITIC Agriculture Technology Co., Ltd., also commented: “Pork is very important in the Chinese culture and the single most important source of animal protein for the Chinese people. As Chinese farmers continue to professionalise, access to PIC genetics and PRRSv resistant pigs will further improve farming productivity and enable our farmers to more efficiently produce safe, disease resistant and sustainable pork. The proposed joint venture with PIC combines the global technological strength of Genus PIC with the Chinese market infrastructure of BCA, which will ultimately benefit Chinese farmers and consumers and help achieve our food security goals.”

This article Genus plc Strategic porcine collaboration in China was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc Karim Bitar Chief Executive Officer steps down from the board https://www.directorstalkinterviews.com/genus-plc-karim-bitar-chief-executive-officer-steps-down-from-the-board/412770524 Mon, 25 Mar 2019 07:41:35 +0000 https://www.directorstalkinterviews.com/?p=770524 Genus plc (LON: GNS), a leading global animal genetics company, announced that Karim Bitar, Chief Executive Officer, will be stepping down from the Board from 16 September 2019. Karim will be taking the Chief Executive Officer position at ConvaTec Group Plc from 30 September 2019. Karim has committed to remain with Genus and continue in ...

This article Genus plc Karim Bitar Chief Executive Officer steps down from the board was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc (LON: GNS), a leading global animal genetics company, announced that Karim Bitar, Chief Executive Officer, will be stepping down from the Board from 16 September 2019. Karim will be taking the Chief Executive Officer position at ConvaTec Group Plc from 30 September 2019. Karim has committed to remain with Genus and continue in his role until 16 September, to achieve an orderly succession and transition process, while continuing to drive business performance.

“During Karim’s eight years at Genus as Chief Executive, the Company has been transformed into a world-leading animal genetics company, truly fulfilling its vision to pioneer animal genetic improvement to help nourish the world. He has led the Company’s transformation and is leaving the Company in excellent shape with a world-class leadership team, world-class genetics and innovative technology platforms to enable us to pursue many exciting global opportunities,” said Bob Lawson Chair of Genus. “His legacy is the creation of an outstanding global team that will sustain the Company’s growth, while serving customers with an unparalleled range of products and services. Karim has provided the Company with many years of strong leadership, and the Board and I remain excited by the Company’s future prospects. On behalf of the Board and all at Genus, I wish Karim well for the future and thank him for his considerable contribution during his time with the Company.”

Karim Bitar said “It has been a great privilege to lead such a talented group of people and develop a leading global agricultural biotechnology company focused on animal genetics. Genus is in a very strong strategic and financial position, with significant growth prospects and I will miss the team tremendously when I eventually leave in September.”

The Board has commenced a search to identify his successor and a further announcement will be made in due course.

This article Genus plc Karim Bitar Chief Executive Officer steps down from the board was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc 11.8% Potential Upside Indicated by HSBC https://www.directorstalkinterviews.com/genus-plc-11-8-potential-upside-indicated-by-hsbc/412769772 Fri, 15 Mar 2019 11:10:19 +0000 https://www.directorstalkinterviews.com/?p=769772 Genus plc with EPIC/TICKER (LON:GNS) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ this morning by analysts at HSBC. Genus plc are listed in the Health Care sector within UK Main Market. HSBC have set a target price of 2700 GBX on its stock. This indicates the analyst now ...

This article Genus plc 11.8% Potential Upside Indicated by HSBC was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc with EPIC/TICKER (LON:GNS) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ this morning by analysts at HSBC. Genus plc are listed in the Health Care sector within UK Main Market. HSBC have set a target price of 2700 GBX on its stock. This indicates the analyst now believes there is a potential upside of 11.8% from the opening price of 2416 GBX. Over the last 30 and 90 trading days the company share price has increased 118 points and increased 208 points respectively. The 52 week high share price is 2998 GBX while the 52 week low for the stock is 2090 GBX.

Genus plc has a 50 day moving average of 2,295.44 GBX and a 200 Day Moving Average share price is recorded at 2,472.13. There are currently 65,046,344 shares in issue with the average daily volume traded being 110,569. Market capitalisation for LON:GNS is £1,591,033,574 GBP.

This article Genus plc 11.8% Potential Upside Indicated by HSBC was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus Plc Performed well in challenging markets and made substantial strategic progress https://www.directorstalkinterviews.com/genus-plc-performed-well-in-challenging-markets-and-made-substantial-strategic-progress/412768299 Thu, 28 Feb 2019 08:15:43 +0000 https://www.directorstalkinterviews.com/?p=768299 Genus Plc (LON:GNS), a leading global animal genetics company, announced its unaudited interim results for the six months ended 31 December 2018. 2019 H1 Highlights · Genus achieved strong strategic progress and performed solidly. Adjusted profit before tax equalled the record of the prior period, despite the challenging environment caused by the rapid spread of ...

This article Genus Plc Performed well in challenging markets and made substantial strategic progress was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus Plc (LON:GNS), a leading global animal genetics company, announced its unaudited interim results for the six months ended 31 December 2018.

2019 H1 Highlights

· Genus achieved strong strategic progress and performed solidly. Adjusted profit before tax equalled the record of the prior period, despite the challenging environment caused by the rapid spread of African Swine Fever (‘ASF’) in China. Genus expects to perform in line with the Board’s expectations for the full year.

Financial Highlights

· Revenue of £238.8m was unchanged in actual and constant currency. Bovine revenue increased 2% (4% in constant currency) with strong sexed genetics revenue growth of 28%, while porcine revenue declined 1% (2% in constant currency) due to fewer animal shipments in China. Strategically important porcine royalty revenue increased strongly by 12% (11% in constant currency).

· Adjusted operating profit including joint ventures and excluding gene editing increased 2% (3% in constant currency) led by continued good growth in ABS, while increasing investment in R&D as planned. Adjusted profit before tax increased 1% to £29.2m (2% in constant currency).

· Statutory loss before tax of £6.8m (2017: £14.3m profit) primarily due to larger non-cash fair value movements on biological assets and a Guaranteed Minimum Pension (‘GMP’) equalisation charge in respect of legacy pension schemes (see below for further details).

· Adjusted basic earnings per share were 12% lower at 35.8p (11% in constant currency) due to a one-time deferred tax credit of £3.7m in the prior year relating to the tax reforms in the US. The statutory basic loss per share was 11.7p (2017: 69.0p profit per share), reflecting the GMP equalisation charge in the current year and a prior year US deferred tax credit of £32.0m from the US tax reforms.

· Free cash outflow1 of £5.3m (2017: £7.5m inflow) following planned capital investments in growing the IntelliGen® global production base and in Genus One, a new global enterprise system.

· Net debt reduced to £85.3m (2017: £113.4m) and net debt to EBITDA2 ratio of 1.1x (2017: 1.4x), following the payments made under the previously announced strategic collaboration with Møllevang Genetics in July 2018 and successful 5% equity placing in December 2018, which raised £66.5m net of fees.

· Interim dividend increased 10% to 8.9 pence per share payable on 4 April 2019.

Operational and Strategic Highlights3

· ABS – Strong first half performance with continued growth in Sexcel®, our high fertility sexed genetics product produced with IntelliGen technology, and rapid growth in our differentiated beef genetics

o Volume growth of 7%, with sexed genetics up 26% and beef up 24%

o Operating profit growth of 10% in constant currency

o IntelliGen production successfully commenced in three new sites around the world, adding to the existing operations in the US, India and Norway

· PIC volumes and operating profit growth of 1% (2% in actual currency) impacted as expected by the outbreak of ASF across China. Operating profit growth of 7% in constant currency excluding China

o Royalty revenue up 11% with growth in all regions

o Volume growth excluding China of 5%, with particular strength in Latin America and Spain

o Encouraging early results from the strategic collaboration with Møllevang Genetics

o Transport restrictions imposed in China to control ASF caused volumes in China to be 49% lower resulting in profit reducing by approximately £3m compared to same period in the prior year

· Research and development investment increased as planned by 10%, primarily from continued investment in gene editing and the IntelliGen platform

o Continued good progress with the PRRSv programme4

o Strong results continue in our leading dairy, beef and porcine genomic selection programmes

o Integration of Møllevang’s genetics with PIC’s product development programme commenced with encouraging early results

Commenting, Karim Bitar, Chief Executive said:

“Genus performed well in challenging markets and made substantial strategic progress in the first half of the 2019 fiscal year. ABS continued to grow profit in double digits, driven by a combination of the success of Sexcel and NuEra, our proprietary beef genetics. Genus is well placed to benefit from and drive the accelerating market trend of dairy customers using sexed and beef genetics in combination.

“As anticipated, PIC was affected negatively by ASF in China but grew strongly in Europe and Latin America and we successfully commenced our strategic relationship with Møllevang Genetics. Our gene editing programme for PRRSv resistance in pigs made good progress and we have substantially increased the number of animals carrying the edit while continuing to engage constructively with regulatory authorities.

“We anticipate growing in the second half and performing in line with the Board’s expectations in constant currency for the full year. The Board has approved an interim dividend of 8.9 pence per share, an increase of 10% on last year’s interim dividend.”

This article Genus Plc Performed well in challenging markets and made substantial strategic progress was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc 15.8% Potential Upside Indicated by HSBC https://www.directorstalkinterviews.com/genus-plc-15-8-potential-upside-indicated-by-hsbc/412767000 Tue, 12 Feb 2019 10:55:07 +0000 https://www.directorstalkinterviews.com/?p=767000 Genus plc using EPIC/TICKER code (LON:GNS) had its stock rating noted as ‘Initiates/Starts’ with the recommendation being set at ‘BUY’ this morning by analysts at HSBC. Genus plc are listed in the Health Care sector within UK Main Market. HSBC have set a target price of 2650 GBX on its stock. This now indicates the ...

This article Genus plc 15.8% Potential Upside Indicated by HSBC was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc using EPIC/TICKER code (LON:GNS) had its stock rating noted as ‘Initiates/Starts’ with the recommendation being set at ‘BUY’ this morning by analysts at HSBC. Genus plc are listed in the Health Care sector within UK Main Market. HSBC have set a target price of 2650 GBX on its stock. This now indicates the analyst believes there is a possible upside of 15.8% from the opening price of 2288 GBX. Over the last 30 and 90 trading days the company share price has increased 38 points and increased 100 points respectively. The 1 year high share price is 2998 GBX while the 52 week low for the stock is 2090 GBX.

Genus plc has a 50 day moving average of 2,275.49 GBX and the 200 Day Moving Average price is recorded at 2,505.32. There are currently 65,045,705 shares in issue with the average daily volume traded being 74,962. Market capitalisation for LON:GNS is £1,501,254,871 GBP.

This article Genus plc 15.8% Potential Upside Indicated by HSBC was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc 11.1% Potential Upside Indicated by Kepler Cheuvreux https://www.directorstalkinterviews.com/genus-plc-11-1-potential-upside-indicated-by-kepler-cheuvreux/412762584 Thu, 06 Dec 2018 11:00:38 +0000 https://www.directorstalkinterviews.com/?p=762584 Genus plc with EPIC/TICKER (LON:GNS) has had its stock rating noted as ‘Upgrades’ with the recommendation being set at ‘BUY’ today by analysts at Kepler Cheuvreux. Genus plc are listed in the Health Care sector within UK Main Market. Kepler Cheuvreux have set their target price at 2630 GBX on its stock. This indicates the ...

This article Genus plc 11.1% Potential Upside Indicated by Kepler Cheuvreux was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc with EPIC/TICKER (LON:GNS) has had its stock rating noted as ‘Upgrades’ with the recommendation being set at ‘BUY’ today by analysts at Kepler Cheuvreux. Genus plc are listed in the Health Care sector within UK Main Market. Kepler Cheuvreux have set their target price at 2630 GBX on its stock. This indicates the analyst now believes there is a potential upside of 11.1% from the opening price of 2368 GBX. Over the last 30 and 90 trading days the company share price has increased 152 points and decreased 140 points respectively. The 52 week high for the stock is 2998 GBX while the 52 week low for the stock is 2090 GBX.

Genus plc has a 50 day moving average of 2,296.80 GBX and the 200 Day Moving Average price is recorded at 2,537.45. There are currently 61,948,505 shares in issue with the average daily volume traded being 70,317. Market capitalisation for LON:GNS is £1,580,925,388 GBP.

This article Genus plc 11.1% Potential Upside Indicated by Kepler Cheuvreux was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc 1.3% Potential Upside Indicated by Kepler Cheuvreux https://www.directorstalkinterviews.com/genus-plc-1-3-potential-upside-indicated-by-kepler-cheuvreux/412758054 Fri, 07 Sep 2018 09:28:10 +0000 https://www.directorstalkinterviews.com/?p=758054 Genus plc using EPIC/TICKER code (LON:GNS) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ today by analysts at Kepler Cheuvreux. Genus plc are listed in the Health Care sector within UK Main Market. Kepler Cheuvreux have set their target price at 2540 GBX on its stock. This indicates ...

This article Genus plc 1.3% Potential Upside Indicated by Kepler Cheuvreux was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc using EPIC/TICKER code (LON:GNS) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ today by analysts at Kepler Cheuvreux. Genus plc are listed in the Health Care sector within UK Main Market. Kepler Cheuvreux have set their target price at 2540 GBX on its stock. This indicates the analyst now believes there is a potential upside of 1.3% from today’s opening price of 2508 GBX. Over the last 30 and 90 trading days the company share price has decreased 378 points and decreased 150 points respectively. The 1 year high for the share price is 2998 GBX while the 52 week low is 1887 GBX.

Genus plc has a 50 day moving average of 2,856.69 GBX and a 200 Day Moving Average share price is recorded at 2,568.13. There are currently 61,542,467 shares in issue with the average daily volume traded being 113,346. Market capitalisation for LON:GNS is £1,564,409,994 GBP.

This article Genus plc 1.3% Potential Upside Indicated by Kepler Cheuvreux was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc 6.7% Potential Upside Indicated by Liberum Capital https://www.directorstalkinterviews.com/genus-plc-6-7-potential-upside-indicated-by-liberum-capital/412757937 Thu, 06 Sep 2018 10:01:48 +0000 https://www.directorstalkinterviews.com/?p=757937 Genus plc using EPIC/TICKER code (LON:GNS) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ today by analysts at Liberum Capital. Genus plc are listed in the Health Care sector within UK Main Market. Liberum Capital have set their target price at 2400 GBX on its stock. This is indicating ...

This article Genus plc 6.7% Potential Upside Indicated by Liberum Capital was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc using EPIC/TICKER code (LON:GNS) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ today by analysts at Liberum Capital. Genus plc are listed in the Health Care sector within UK Main Market. Liberum Capital have set their target price at 2400 GBX on its stock. This is indicating the analyst believes there is a potential upside of 6.7% from today’s opening price of 2250 GBX. Over the last 30 and 90 trading days the company share price has decreased 614 points and decreased 390 points respectively. The 1 year high share price is 2998 GBX while the 52 week low for the stock is 1864 GBX.

Genus plc has a 50 day moving average of 2,855.63 GBX and a 200 Day Moving Average share price is recorded at 2,566.95. There are currently 4,701,818,759 shares in issue with the average daily volume traded being 105,628. Market capitalisation for LON:GNS is £1,745,663,082 GBP.

This article Genus plc 6.7% Potential Upside Indicated by Liberum Capital was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc 8.4% Potential Decrease Indicated by Kepler Cheuvreux https://www.directorstalkinterviews.com/genus-plc-8-4-potential-decrease-indicated-by-kepler-cheuvreux/412753962 Wed, 04 Jul 2018 09:57:12 +0000 https://www.directorstalkinterviews.com/?p=753962 Genus plc using EPIC/TICKER code (LON:GNS) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ this morning by analysts at Kepler Cheuvreux. Genus plc are listed in the Health Care sector within UK Main Market. Kepler Cheuvreux have set a target price of 2470 GBX on its stock. This ...

This article Genus plc 8.4% Potential Decrease Indicated by Kepler Cheuvreux was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc using EPIC/TICKER code (LON:GNS) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ this morning by analysts at Kepler Cheuvreux. Genus plc are listed in the Health Care sector within UK Main Market. Kepler Cheuvreux have set a target price of 2470 GBX on its stock. This would imply the analyst believes there is a potential downside of -8.4% from the opening price of 2696 GBX. Over the last 30 and 90 trading days the company share price has increased 56 points and increased 426 points respectively. The 1 year high for the share price is 2736 GBX while the year low share price is currently 1652 GBX.

Genus plc has a 50 day moving average of 2,600.33 GBX and a 200 day moving average of 2,426.27. There are currently 61,542,468 shares in issue with the average daily volume traded being 110,708. Market capitalisation for LON:GNS is £1,627,015,888 GBP.

This article Genus plc 8.4% Potential Decrease Indicated by Kepler Cheuvreux was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc 2% Potential Upside Indicated by Liberum Capital https://www.directorstalkinterviews.com/genus-plc-2-potential-upside-indicated-by-liberum-capital/412747162 Mon, 12 Mar 2018 10:34:05 +0000 https://www.directorstalkinterviews.com/?p=747162 Genus plc using EPIC/TICKER code (LON:GNS) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ this morning by analysts at Liberum Capital. Genus plc are listed in the Health Care sector within UK Main Market. Liberum Capital have set a target price of 2400 GBX on its stock. This ...

This article Genus plc 2% Potential Upside Indicated by Liberum Capital was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc using EPIC/TICKER code (LON:GNS) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ this morning by analysts at Liberum Capital. Genus plc are listed in the Health Care sector within UK Main Market. Liberum Capital have set a target price of 2400 GBX on its stock. This now indicates the analyst believes there is a possible upside of 2.0% from the opening price of 2352 GBX. Over the last 30 and 90 trading days the company share price has increased 82 points and decreased 48 points respectively. The 52 week high share price is 2597 GBX while the 52 week low for the share price is 1652 GBX.

Genus plc has a 50 day moving average of 2,405.76 GBX and a 200 Day Moving Average share price is recorded at 2,154.33. There are currently 61,535,102 shares in issue with the average daily volume traded being 75,570. Market capitalisation for LON:GNS is £1,447,305,599 GBP.

This article Genus plc 2% Potential Upside Indicated by Liberum Capital was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc 2.9% Potential Upside Indicated by Liberum Capital https://www.directorstalkinterviews.com/genus-plc-2-9-potential-upside-indicated-by-liberum-capital/412746446 Wed, 28 Feb 2018 10:10:19 +0000 https://www.directorstalkinterviews.com/?p=746446 Genus plc with EPIC/TICKER (LON:GNS) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ this morning by analysts at Liberum Capital. Genus plc are listed in the Health Care sector within UK Main Market. Liberum Capital have set their target price at 2400 GBX on its stock. This would indicate ...

This article Genus plc 2.9% Potential Upside Indicated by Liberum Capital was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc with EPIC/TICKER (LON:GNS) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ this morning by analysts at Liberum Capital. Genus plc are listed in the Health Care sector within UK Main Market. Liberum Capital have set their target price at 2400 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 2.9% from the opening price of 2332 GBX. Over the last 30 and 90 trading days the company share price has decreased 88 points and decreased 48 points respectively. The 1 year high stock price is 2597 GBX while the 52 week low is 1652 GBX.

Genus plc has a 50 day moving average of 2,440.72 GBX and the 200 Day Moving Average price is recorded at 2,139.19. There are currently 42,322,635 shares in issue with the average daily volume traded being 56,575. Market capitalisation for LON:GNS is £1,391,924,030 GBP.

This article Genus plc 2.9% Potential Upside Indicated by Liberum Capital was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc 3.4% Potential Upside Indicated by Liberum Capital https://www.directorstalkinterviews.com/genus-plc-3-4-potential-upside-indicated-by-liberum-capital-2/412745771 Wed, 14 Feb 2018 10:15:16 +0000 https://www.directorstalkinterviews.com/genus-plc-3-4-potential-upside-indicated-by-liberum-capital-2/412745771 Genus plc using EPIC/TICKER code (LON:GNS) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ this morning by analysts at Liberum Capital. Genus plc are listed in the Health Care sector within UK Main Market. Liberum Capital have set a target price of 2400 GBX on its stock. This ...

This article Genus plc 3.4% Potential Upside Indicated by Liberum Capital was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc using EPIC/TICKER code (LON:GNS) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ this morning by analysts at Liberum Capital. Genus plc are listed in the Health Care sector within UK Main Market. Liberum Capital have set a target price of 2400 GBX on its stock. This would imply the analyst believes there is now a potential upside of 3.4% from today’s opening price of 2320 GBX. Over the last 30 and 90 trading days the company share price has decreased 204 points and increased 96 points respectively. The 52 week high for the stock is 2597 GBX while the year low stock price is currently 1652 GBX.

Genus plc has a 50 day moving average of 2,467.49 GBX and a 200 day moving average of 2,116.15. There are currently 61,535,092 shares in issue with the average daily volume traded being 56,730. Market capitalisation for LON:GNS is £1,423,922,029 GBP.

This article Genus plc 3.4% Potential Upside Indicated by Liberum Capital was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc 7.7% Potential Decrease Indicated by Liberum Capital https://www.directorstalkinterviews.com/genus-plc-7-7-potential-decrease-indicated-by-liberum-capital/412745578 Mon, 12 Feb 2018 11:10:55 +0000 https://www.directorstalkinterviews.com/?p=745578 Genus plc using EPIC/TICKER code (LON:GNS) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ today by analysts at Liberum Capital. Genus plc are listed in the Health Care sector within UK Main Market. Liberum Capital have set their target price at 2100 GBX on its stock. This now indicates ...

This article Genus plc 7.7% Potential Decrease Indicated by Liberum Capital was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc using EPIC/TICKER code (LON:GNS) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ today by analysts at Liberum Capital. Genus plc are listed in the Health Care sector within UK Main Market. Liberum Capital have set their target price at 2100 GBX on its stock. This now indicates the analyst believes there is a potential downside of -7.7% from the opening price of 2274 GBX. Over the last 30 and 90 trading days the company share price has decreased 250 points and decreased 19 points respectively. The 1 year high for the stock price is 2597 GBX while the 52 week low for the stock is 1652 GBX.

Genus plc has a 50 day moving average of 2,470.62 GBX and the 200 Day Moving Average price is recorded at 2,111.05. There are currently 61,535,103 shares in issue with the average daily volume traded being 54,796. Market capitalisation for LON:GNS is £1,388,231,924 GBP.

This article Genus plc 7.7% Potential Decrease Indicated by Liberum Capital was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc 17.4% Potential Decrease Indicated by Liberum Capital https://www.directorstalkinterviews.com/genus-plc-17-4-potential-decrease-indicated-by-liberum-capital/412743731 Mon, 15 Jan 2018 09:57:35 +0000 https://www.directorstalkinterviews.com/?p=743731 Genus plc with EPIC/TICKER (LON:GNS) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ this morning by analysts at Liberum Capital. Genus plc are listed in the Health Care sector within UK Main Market. Liberum Capital have set their target price at 2100 GBX on its stock. This would imply ...

This article Genus plc 17.4% Potential Decrease Indicated by Liberum Capital was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>
Genus plc with EPIC/TICKER (LON:GNS) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ this morning by analysts at Liberum Capital. Genus plc are listed in the Health Care sector within UK Main Market. Liberum Capital have set their target price at 2100 GBX on its stock. This would imply the analyst believes there is a potential downside of -17.4% from today’s opening price of 2542 GBX. Over the last 30 and 90 trading days the company share price has decreased 31 points and increased 330 points respectively. The 1 year high for the stock price is 2597 GBX while the 52 week low for the stock is 1652 GBX.

Genus plc has a 50 day moving average of 2,414.85 GBX and the 200 Day Moving Average price is recorded at 2,044.72. There are currently 171,817,173 shares in issue with the average daily volume traded being 47,446. Market capitalisation for LON:GNS is £1,577,760,297 GBP.

This article Genus plc 17.4% Potential Decrease Indicated by Liberum Capital was written by DirectorsTalk Interviews.


©2017 DirectorsTalk Interviews
]]>